RxDoctor Payments DataLook up a doctor →

Paul Azer, MD

Endocrinology · Beverly Hills, CANPI 1336154707

Payments from drug & device makers

$25,448in general payments, 2019–2025

Across 1,212 payments — averaging $21.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$3K
  • Boehringer Ingelheim$3K
  • AbbVie$2K
  • Amgen$2K
  • Insulet Corporation$1K
  • Abbott$1K
  • plus $14K from 54 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Lilly USA, LLC121$2,609
Boehringer Ingelheim95$2,549
AbbVie81$1,736
Amgen(2 entities)67$1,629
Insulet Corporation61$1,421
Abbott76$1,370
Corcept Therapeutics53$1,311
Mannkind Corporation95$1,311
Novo Nordisk79$1,310
Sanofi-aventis U.S. LLC54$1,195
AstraZeneca(2 entities)46$992
Bayer24$714
Radius Health, Inc.26$636
Recordati_rare_diseases_inc.30$561
Xeris Pharmaceuticals, Inc.21$424
Viiv Healthcare Company18$423
Merck26$421
Medtronic(3 entities)10$411
Novartis14$403
Currax Pharmaceuticals LLC28$312
Johnson & Johnson37$299
IBSA Pharma Inc.16$296
Tandem Diabetes Care, Inc.10$286
Dexcom, Inc.12$241
Madrigal Pharmaceuticals13$225
BD7$222
Ascensia Diabetes Care US Inc.7$160
Kyowa Kirin, Inc.5$135
Embecta Corp.5$128
Alvogen Inc5$123
Endo Pharmaceuticals Inc.7$119
Regeneron Healthcare Solutions, Inc.3$117
Lifescan, Inc.5$106
Alfasigma USA, Inc.3$85
Lexicon Pharmaceuticals, Inc.3$74
Ipsen Biopharmaceuticals, Inc3$73
Zealand Pharma US, Inc.3$71
Antares Pharma, Inc.3$71
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC3$68
Neurocrine Biosciences, Inc.2$62
EUSA Pharma (US) LLC3$61
GRT US Holding, Inc.2$61
Esperion Therapeutics, Inc.3$58
Halozyme Inc2$48
Shire North American Group Inc2$48
Eisai Inc.2$46
Intra-sana Laboratories2$39
Amneal Pharmaceuticals LLC2$36
Tolmar, Inc.2$35
Acella Pharmaceuticals, LLC2$30
Cequr Corporation1$29
Biohaven Pharmaceutical Holding Company Ltd.1$27
Bigfoot Biomedical Inc1$26
Sequel Med Tech, LLC1$25
Exact Sciences1$24
Vivus LLC1$23
Amryt Pharma Holdings Ltd1$23
Sanofi1$20
Kowa Pharmaceuticals America, Inc.1$19
Biohaven Pharmaceuticals, Inc.1$19

How this compares

$25,448 in reported general payments places this provider in the 90th percentile of 58 endocrinology providers in California.

See all endocrinology providers in California

Medicare billing

Part B allowed, 2024
$436,564
Medicare patients
1,095
Services billed
4,702

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other endocrinology in Beverly Hills

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →